Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1–Negative Human Lung Cancers
Abstract
Purpose: Immunotherapy targeting the PD-1/PD-L1 pathway has changed the treatment landscape of non–small cell lung carcinoma (NSCLC). We demonstrated that HHLA2, a newly identified immune inhibitory molecule, was widely expressed in NSCLC. We now compared the expression and function of PD-L1 with alternative immune checkpoints, B7x and HHLA2.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 12, 2018
- Source ID
- 10.1158/1078-0432.ccr-17-2924
Entities
People
- Alain Borczuk
- Amer Assal
- Balazs Halmos
- Haiying Cheng
- Juan Lin
- Murali Janakiram
- Roman Perez-soler
- Xiaoxin Ren
- Xingxing Zang
Organizations
- Albert Einstein College of Medicine
- Columbia University
- National Institutes of Health
- United States Department of Defense
- Weill Cornell Medicine